Your browser doesn't support javascript.
loading
Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study.
Slieker, Roderick C; Donnelly, Louise A; Fitipaldi, Hugo; Bouland, Gerard A; Giordano, Giuseppe N; Åkerlund, Mikael; Gerl, Mathias J; Ahlqvist, Emma; Ali, Ashfaq; Dragan, Iulian; Elders, Petra; Festa, Andreas; Hansen, Michael K; van der Heijden, Amber A; Mansour Aly, Dina; Kim, Min; Kuznetsov, Dmitry; Mehl, Florence; Klose, Christian; Simons, Kai; Pavo, Imre; Pullen, Timothy J; Suvitaival, Tommi; Wretlind, Asger; Rossing, Peter; Lyssenko, Valeriya; Legido Quigley, Cristina; Groop, Leif; Thorens, Bernard; Franks, Paul W; Ibberson, Mark; Rutter, Guy A; Beulens, Joline W J; 't Hart, Leen M; Pearson, Ewan R.
Afiliação
  • Slieker RC; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
  • Donnelly LA; Department of Epidemiology and Data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands.
  • Fitipaldi H; Population Health & Genomics, School of Medicine, University of Dundee, Dundee, U.K.
  • Bouland GA; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
  • Giordano GN; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
  • Åkerlund M; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
  • Gerl MJ; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
  • Ahlqvist E; Lipotype GmbH, Dresden, Germany.
  • Ali A; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
  • Dragan I; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Elders P; Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Festa A; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands.
  • Hansen MK; Eli Lilly Regional Operations GmbH, Vienna, Austria.
  • van der Heijden AA; 1st Medical Department, LK Stockerau, Niederösterreich, Austria.
  • Mansour Aly D; Cardiovascular and Metabolic Disease Research, Janssen Research & Development, Spring House, PA.
  • Kim M; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands.
  • Kuznetsov D; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
  • Mehl F; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Klose C; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicines, King's College London, London, U.K.
  • Simons K; Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Pavo I; Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Pullen TJ; Lipotype GmbH, Dresden, Germany.
  • Suvitaival T; Lipotype GmbH, Dresden, Germany.
  • Wretlind A; Eli Lilly Regional Operations GmbH, Vienna, Austria.
  • Rossing P; Department of Diabetes, Guy's Campus, King's College London, London, U.K.
  • Lyssenko V; Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, U.K.
  • Legido Quigley C; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Groop L; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Thorens B; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Franks PW; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Ibberson M; Department of Clinical Science, Center for Diabetes Research, University of Bergen, Bergen, Norway.
  • Rutter GA; Genomics, Diabetes and Endocrinology Unit, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Skåne University Hospital, Malmö, Sweden.
  • Beulens JWJ; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • 't Hart LM; Cardiovascular and Metabolic Disease Research, Janssen Research & Development, Spring House, PA.
  • Pearson ER; Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Clinical Research Centre, Lund University, SUS, Malmö, Sweden.
Diabetes ; 70(11): 2683-2693, 2021 11.
Article em En | MEDLINE | ID: mdl-34376475
ABSTRACT
Type 2 diabetes is a multifactorial disease with multiple underlying aetiologies. To address this heterogeneity, investigators of a previous study clustered people with diabetes according to five diabetes subtypes. The aim of the current study is to investigate the etiology of these clusters by comparing their molecular signatures. In three independent cohorts, in total 15,940 individuals were clustered based on five clinical characteristics. In a subset, genetic (N = 12,828), metabolomic (N = 2,945), lipidomic (N = 2,593), and proteomic (N = 1,170) data were obtained in plasma. For each data type, each cluster was compared with the other four clusters as the reference. The insulin-resistant cluster showed the most distinct molecular signature, with higher branched-chain amino acid, diacylglycerol, and triacylglycerol levels and aberrant protein levels in plasma were enriched for proteins in the intracellular PI3K/Akt pathway. The obese cluster showed higher levels of cytokines. The mild diabetes cluster with high HDL showed the most beneficial molecular profile with effects opposite of those seen in the insulin-resistant cluster. This study shows that clustering people with type 2 diabetes can identify underlying molecular mechanisms related to pancreatic islets, liver, and adipose tissue metabolism. This provides novel biological insights into the diverse aetiological processes that would not be evident when type 2 diabetes is viewed as a homogeneous disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article